Novel Treatment for Thymidine Kinase 2 Deficiency (TK2d) Myopathy
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
MitoRainbow Therapeutics, Inc.
Award Date
Award Amount
100,000
Program Name
Small Business Research Loan
Program Category
Business Financing
Principal Investigator
Curtis Cui
Fiscal Year
2020
Region
Research Triangle
Project Description:
MitoRainbow Therapeutics, Inc. is developing new treatments for devastating mitochondrial metabolic diseases. Genetic deficiency of thymidine kinase 2 (TK2) results in loss of mitochondria function, severe myopathy, and early death in children. The company was awarded a $100,000 SRL to advance development of MTR1, the company’s first drug candidate for TK2 deficiency.